• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Evolving Role of Locally Delivered Checkpoint Inhibitors in Non-muscle-invasive Bladder Cancer.

作者信息

Hayne Dickon, Redfern Andrew

机构信息

Medical School, The University of Western Australia, Perth, Australia; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, Australia; Department of Urology, Fiona Stanley Hospital, Murdoch, Australia.

Medical School, The University of Western Australia, Perth, Australia; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Murdoch, Australia.

出版信息

Eur Urol. 2022 Dec;82(6):611-612. doi: 10.1016/j.eururo.2022.08.032. Epub 2022 Sep 22.

DOI:10.1016/j.eururo.2022.08.032
PMID:36153248
Abstract
摘要

相似文献

1
The Evolving Role of Locally Delivered Checkpoint Inhibitors in Non-muscle-invasive Bladder Cancer.局部递送的检查点抑制剂在非肌层浸润性膀胱癌中不断演变的作用
Eur Urol. 2022 Dec;82(6):611-612. doi: 10.1016/j.eururo.2022.08.032. Epub 2022 Sep 22.
2
Urothelial carcinoma in the era of immune checkpoint inhibitors.免疫检查点抑制剂时代的尿路上皮癌。
Immunotherapy. 2021 Aug;13(11):953-964. doi: 10.2217/imt-2021-0042. Epub 2021 Jun 29.
3
Immunotherapy and non-muscle-invasive bladder cancer: an idea from the 19th century.免疫疗法与非肌层浸润性膀胱癌：源于19世纪的一个想法。
Expert Rev Anticancer Ther. 2021 Jul;21(7):689-692. doi: 10.1080/14737140.2021.1921578. Epub 2021 May 3.
4
Emerging role of checkpoint inhibition in localized bladder cancer.检查点抑制在局限性膀胱癌中的新作用。
Urol Oncol. 2016 Dec;34(12):548-555. doi: 10.1016/j.urolonc.2016.09.004. Epub 2016 Oct 21.
5
Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, what's new?肌肉浸润性膀胱癌新辅助治疗中的免疫疗法，有哪些新进展？
Immunotherapy. 2021 Apr;13(6):459-463. doi: 10.2217/imt-2020-0285. Epub 2021 Feb 9.
6
[Immunotherapy in advanced urothelial cancer].[晚期尿路上皮癌的免疫疗法]
Magy Onkol. 2021 Dec 7;65(4):339-346. Epub 2021 Nov 10.
7
Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.肌层浸润性和转移性膀胱癌的系统治疗：当前趋势和未来前景。
Future Oncol. 2016 Sep;12(17):2049-58. doi: 10.2217/fon-2016-0155. Epub 2016 Jun 16.
8
[Systemic treatment of bladder cancer].[膀胱癌的全身治疗]
Urologe A. 2021 Sep;60(9):1167-1174. doi: 10.1007/s00120-021-01535-3. Epub 2021 May 27.
9
Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.免疫检查点抑制剂在高危非肌肉浸润性膀胱癌治疗中的应用。范围综述。
Urol Oncol. 2022 Sep;40(9):409.e1-409.e8. doi: 10.1016/j.urolonc.2022.02.003. Epub 2022 Feb 26.
10
Immune checkpoint inhibitors: a new frontier in bladder cancer.免疫检查点抑制剂：膀胱癌治疗的新前沿
World J Urol. 2016 Jan;34(1):49-55. doi: 10.1007/s00345-015-1709-y. Epub 2015 Oct 20.

引用本文的文献

1
Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.甲硫氨酸驱动的YTHDF1表达通过减弱RIG-I调节的免疫反应和增强eIF5B-PD-L1轴促进膀胱癌进展。
Cell Death Differ. 2025 Apr;32(4):776-791. doi: 10.1038/s41418-024-01434-y. Epub 2024 Dec 13.
2
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer.膀胱癌现有全身用药及新兴疗法的新型给药机制
Bladder Cancer. 2023 Jun 27;9(2):109-123. doi: 10.3233/BLC-220114. eCollection 2023.